Persistent Trophoblastic Disease in Trophoblastic Disease Center in the Czech Republic in 1955 – 2007

Česká verzia

Authors: M. Zavadil; J. Feyereisl; L. Krofta; P. Šafář; R. Turyna
Authors place of work: III. lékařská fakulta Karlovy Univerzity, Praha ; Ústav pro péči o matku a dítě, ředitel doc. MUDr. Jaroslav Feyereisl, CSc. ; Katedra gynekologie a porodnictví IPVZ, Praha ; Centrum pro trofoblastickou nemoc v ČR, vedoucí doc. MUDr. Miloš Zavadil, DrSc.
Published in the journal: Ceska Gynekol 2008; 73(2): 73-79

Summary

Objective:
To define persistent trophoblastic disease as a clinical entity of gestational trophoblastic disease. To describe its classification, treatment and follow-up.

Type of study:
Retrospective analysis.

Setting:
Trophoblastic Disease Center (TDC) in the Czech Republic TDC-CZ, Institute for the Care of Mother and Child, Prague.

Methods:
This study analyzes data from the Trophoblastic Disease Center consisting of 396 choriocarcinomas, 512 proliferative moles, 798 complete hydatid moles, 1299 partial hydatid moles, and 2105 persistent trophoblastic invasions treated at the TDC up to the year 2007. The study includes also 2615 cases of trophoblastic disease which documented by gynecologists and pathologists of the Czech Republic and registered in the TDC-CZ.

Results:
Persistent trophoblastic disease was defined and described in detail as follows:

1. Differentiating autothonic hCG, produced by the gestational trophoblast, from so-called “phantom hCG,” hypophyseal hCG and hCG during PLL-Q and PLL-U syndrome.

2. Evaluating the level and length of persistence of hCG relevant for the diagnosis of persistent trophoblastic disease.

3. Identifying three types of persistent trophoblastic disease:

A. Non-metastatic

B. Metastatic low-risk

C. Metastatic high-risk

4. Described treatment, indications, and choice of various chemotherapeutic protocols in individual types of persistent trophoblastic disease as well as its follow-up.

Conclusion:
This study enables the differentiation of persistent trophoblastic disease in general gynecologic and obstetric clinical practice, by evaluating the presence, level, and length of persistence of hCG, and thus allowing for timely referral of the patient to the Trophoblastic Disease Center in the Czech Republic.

Key words:
persistent trophoblastic disease, diagnosis, treatment, classification, follow-up

Zdroje

1. Cole, LA. Phantom hCG and phantom choriokarcinoma. Gynecol Oncol, 1998, 71, p. 325–329.

2. Cole, LA., Rinne, KM., Shahabi, S., Omrami, A. False positive hCG levels leading to unnecessery surgery and chemotherapy, and needless occurrences of diabetes and coma. Clin Chem, 1999, 45, p. 313–314.

3. FIQO committee report. FIQO staging for gestational trophoblastic neoplasm 2000. Int J Gynec Obstet, 2002, 77, p. 285–287.

4. Fischer, RA., Soterion, B., Meredith, L., et al. Previous hydatiforme mole identified as the causative pregnancy of choriocarcinoma following birth of normal twins. Int J Gynecol Cancer, 1984, 5, p. 64–70.

5. Goldstain, DP., Zanten-Przybysz, I., Bernstain, MR., Berkowicz, RS. FIGO staging system for gestational trophoblastic tumors. J Reprod Med, 1998, 43, p. 37–43.

6. Grunfield, AW. Gestational trophoblastic disease: Prognostic variables and staging. Semin Oncol, 1995, 2, p. 142–148.

7. Hancock, BW., Welch, EM., Gillaspie, AM., Newlands, ES. A retrospective comparison of current and proposed staging a scoring systéme for persistent gestational trophoblastic disease. Int J Gynecol Cancer, 2000, 10, p. 318–322.

8. Ndan, HY. The FIGO staging for gestational trophoblastic neoplazm 2000. FIGO Report, Int J Gynecol Obstet, 2000, 77, p. 285–287.

9. Rotmensch, S., Cole, LA. False diagnostic and needles therapy of presumed malignant disease in women with false – positive human chorionic gonadotropin concentrations. Lancet, 2000, 355, p. 712–715.

10. Royal College of Obstetricians and Gynecologist. The management of gestational trophoblastic disease. Guideline No. 19 London. RCOG 1999.

11. Spiller, CA. Centralised treatment, entry to trials and survival. Br J Cancer, 1994, 70, p. 352–362.

12. Takenchi, S. The report of the Registration Committee of the Japan Society of Gestational Trophoblastic diseases. Acta Obstet Gynecol Japonica, 1987, 39, p. 871–880.

13. Zavadil, M. Patomorfologie trofoblastické nemoci. Habilitační disertace, FVL UK, Praha 1968, s. 196.

14. Zavadil, M. Trophoblastic Disease III. Acta Univ. Carol. Med., 1973, 19, p. 65–107.

15. Zavadil, M., Feyereisl, J., Šafář, P. Placental Site Trophoblastic Tumor a Epitheloid Trophoblastic Tumor v souboru maligních tumorů trofoblastu zachycených v Centru pro trofoblastickou nemoc v ČR v letech 1955–2000. Čes Gynek, 2000, 65, 5, s. 317–323.

16. Zavadil, M., Feyereisl, J., Krofta, L., et al. Syndrom of persistent low levels of human chorionic gonadotrophin. Čes. Gynek., 71, 2006, s. 136–142